Reaction
Renal Infarct reporting signals
As of the last recalculation, Renal Infarct appears in 1,438 FAERS reports alongside 35 co-occurring drug terms. The strongest observed disproportionality signal is AMPHETAMINE (PRR 39.1).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Amphetamine | 22 | 39.1 | 39.2 |
| Testosterone | 55 | 35.4 | 35.4 |
| Basiliximab | 17 | 21.2 | 21.2 |
| Nevirapine | 13 | 21.0 | 21.1 |
| Abacavir Sulfate | 14 | 21.0 | 21.0 |
| Heparin Sodium | 19 | 20.3 | 20.3 |
| Ampicillin | 11 | 19.4 | 19.4 |
| Ampicillin Sodium | 11 | 19.4 | 19.4 |
| Sumatriptan Succinate | 27 | 15.7 | 15.8 |
| Tenofovir Disoproxil Fumarate Tablets | 9 | 15.2 | 15.2 |
| Inclisiran | 8 | 14.5 | 14.5 |
| Anti-Thymocyte Globulin (Rabbit) | 8 | 14.4 | 14.4 |
| Remdesivir | 13 | 14.2 | 14.3 |
| Zidovudine | 13 | 14.2 | 14.2 |
| Rizatriptan Benzoate | 9 | 12.9 | 12.9 |
| Amitriptyline Hydrochloride | 15 | 12.5 | 12.5 |
| Ketoprofen | 11 | 12.2 | 12.2 |
| Cisplatin | 61 | 11.8 | 11.8 |
| Methimazole | 6 | 11.1 | 11.1 |
| Norepinephrine | 7 | 9.5 | 9.5 |
| Emicizumab | 8 | 9.4 | 9.4 |
| Sumatriptan | 24 | 9.3 | 9.3 |
| Norepinephrine Bitartrate | 9 | 9.1 | 9.1 |
| Alteplase | 9 | 8.7 | 8.7 |
| Dabigatran Etexilate | 43 | 8.2 | 8.2 |
| Testosterone Cypionate | 5 | 8.1 | 8.1 |
| Dabigatran Etexilate Mesylate | 39 | 8.0 | 8.0 |
| Temozolomide | 11 | 7.6 | 7.6 |
| Cetuximab | 15 | 7.0 | 7.0 |
| Gemcitabine Hydrochloride | 21 | 5.8 | 5.8 |
| Irinotecan Hydrochloride | 5 | 5.6 | 5.6 |
| Gemcitabine | 15 | 5.6 | 5.6 |
| Tenofovir Disoproxil Fumarate | 12 | 5.3 | 5.3 |
| Drospirenone And Ethinyl Estradiol | 16 | 5.3 | 5.3 |
| Encorafenib | 3 | 4.4 | 4.4 |